Arena Pharmaceuticals, Inc. (ARNA) financial statements (2020 and earlier)

Company profile

Business Address 6154 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:74044627191156163222
Cash and cash equivalents24316115991156163222
Short-term investments49628588    
Other undisclosed cash, cash equivalents, and short-term investments  24    
Receivables252205411
Inventory, net of allowances, customer advances and progress billings   7101113
Inventory   7101113
Contract with customer, asset 1
Disposal group, including discontinued operation  17    
Other undisclosed current assets199(10)2444
Total current assets:760461281120175182249
Noncurrent Assets
Property, plant and equipment25233044728377
Long-term investments and receivables3718224    
Long-term investments3718224    
Intangible assets, net (including goodwill)   28810
Intangible assets, net (excluding goodwill)   28810
Deposits noncurrent assets     11
Disposal group, including discontinued operation, noncurrent assets  1   
Other noncurrent assets181043233
Deferred tax assets, net110     
Other undisclosed noncurrent assets  (1)  (1)(1)
Total noncurrent assets:4142265849829491
TOTAL ASSETS:1,174687339169257276340
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities251681281017
Accounts payable6626234
Accrued liabilities5111131
Employee-related liabilities14955554
Accounts payable and other accrued liabilities7
Debt      2
Derivative instruments and hedges, liabilities     0 
Restructuring reserve   0  
Provision for loss on contracts      1
Estimated litigation liability  24    
Disposal group, including discontinued operation  28    
Deferred revenue and credits135211538
Other undisclosed current liabilities19141216204114
Total current liabilities:45307264506771
Noncurrent Liabilities
Long-term debt and lease obligation      71
Capital lease obligations     71
Liabilities, other than long-term debt121238893106
Deferred revenue and credits128893102
Other liabilities12111   
Derivative instruments and hedges, liabilities      5
Other undisclosed noncurrent liabilities46495862   
Total noncurrent liabilities:585160658893177
Total liabilities:10381132129138161248
Stockholders' equity
Stockholders' equity attributable to parent1,07160620740544792
Common stock0000000
Additional paid in capital2,1732,1071,6991,4421,4311,3131,294
Accumulated other comprehensive income (loss)1(0)(1)(3)(1)36
Accumulated deficit(1,103)(1,501)(1,490)(1,399)(1,376)(1,268)(1,208)
Stockholders' equity attributable to noncontrolling interest   0   
Total stockholders' equity:1,07160620740544792
Other undisclosed liabilities and equity    6568 
TOTAL LIABILITIES AND EQUITY:1,174687339169257276340

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues8061821124383781
Revenue, net2720 6
Cost of revenue(14)(1)(0)(14)(16)(6) 
Cost of goods and services sold   (9)(9)(6) 
Gross profit:7921721110223181
Operating expenses(309)(162)(113)(127)(126)(136)(136)
Other undisclosed operating income     032
Operating income (loss):483(145)(92)(17)(103)(105)(23)
Nonoperating income (expense)256(4)(6)(5)454
Investment income, nonoperating279000500
Other nonoperating income (expense)33201(2)0
Interest and debt expense(5)(6)(6)(7)(7)(7)(7)
Other undisclosed income from continuing operations before equity method investments, income taxes   7777
Income (loss) from continuing operations before equity method investments, income taxes:503(145)(102)(23)(108)(61)(19)
Other undisclosed income from continuing operations before income taxes56     
Income (loss) from continuing operations before income taxes:508(139)(102)(23)(108)(61)(19)
Income tax expense (benefit)(110)110     
Other undisclosed income from continuing operations  6    
Income (loss) from continuing operations:398(29)(96)(23)(108)(61)(19)
Income (loss) from discontinued operations (1)3    
Income (loss) before gain (loss) on sale of properties:398(29)(93)(23)(108)(61)(19)
Other undisclosed net loss   (0)   
Net income (loss):398(29)(93)(23)(108)(61)(19)
Net income attributable to noncontrolling interest  10   
Net income (loss) available to common stockholders, diluted:398(29)(91)(23)(108)(61)(19)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):398(29)(93)(23)(108)(61)(19)
Other comprehensive income (loss)1(0)     
Other undisclosed comprehensive income (loss)(0)02(2)   
Comprehensive income (loss):399(29)(91)(25)(108)(61)(19)
Comprehensive income, net of tax, attributable to noncontrolling interest  10   
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    (4)(3)0
Comprehensive income (loss), net of tax, attributable to parent:399(29)(90)(24)(112)(63)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: